- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) , with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.
Patent protection for originator ranibizumab is expected to expire in 2020 in the US and 2022 in the EU, and biosimilar development is well underway .
Intas Pharmaceuticals launched their Razumab biosimilar in India in 2015. Formycon/Santo Holdings' FYB201 has completed Phase 3 clinical evaluation in direct comparision with the originator product (NCT02611778) and Samsung Bioepis' SB11 has entered Phase 3 evaluation in trial NCT03150589. Results from these Phase 3 trials have yet to be disclosed.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Approved drug?||Yes (FDA (2006), EMA (2007))|
|International Nonproprietary Names|
|Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2|
|GtoPdb PubChem SID||178103385|
|Search PubMed clinical trials||ranibizumab|
|Search PubMed titles||ranibizumab|
|Search PubMed titles/abstracts||ranibizumab|